A Study of Osimertinib with or without Platinum Plus Pemetrexed Chemotherapy as First-line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation- Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
Enrolling By Invitation
18 years - 99 years
All
Phase
3
10 participants needed
1 Location
Brief description of study
The purpose of this study is to try to find out if an experimental combination of an oral medication called osimertinib when used in combination with chemotherapy is more effective than giving osimertinib alone for the treatment of non-small cell lung cancer (NSCLC). Eligible subjects will be adult subjects with NSCLC.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Non-small Cell Lung Cancer
-
Age: 18 years - 99 years
-
Gender: All
Male or Female 18 or older Locally Advanced or Metastatic Non-small Cell Lung Cancer
Updated on
04 Aug 2024.
Study ID: 843909
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
